Antimicrobials, including antibiotics, antifungals, antivirals, and antiparasitics, are designed to target and eliminate harmful microorganisms. Yet many people experience recurring or persistent infections despite treatment. Two survival strategies that help explain this pattern are biofilms and persister cells.^{[1] [2] [3]}

These two concepts are related but not identical. Biofilms help microbes organize into protected communities, while persister cells are a small subpopulation that can survive antimicrobial exposure without becoming genetically resistant. Together, they help explain why some infections are so difficult to fully clear.^{[1] [2]}

Key idea: Persister cells are not the same as antibiotic-resistant mutants. They are genetically susceptible cells in a dormant or low-metabolism state that temporarily tolerate treatment and may later repopulate the infection.^{[1] [2] [3]}

Understanding Biofilms: The Protective Shield

Biofilms are structured communities of microorganisms that attach to a surface and become embedded in a self-produced matrix. This matrix commonly contains polysaccharides, proteins, and extracellular DNA, and it helps shelter the organisms inside.^{[1] [2] [3]}

• What they are made of: Biofilms are built from materials secreted by the microbes themselves, including protective sugars, proteins, and other matrix components. Dental plaque is a familiar everyday example of a biofilm.
• Why they matter: The biofilm matrix can slow penetration of antimicrobials and can alter nutrient availability, oxygen levels, and microbial behavior within the community. These changes help make biofilm-associated infections more difficult to eradicate.^{[1] [2] [3]}

Understanding Persister Cells: The Hibernating Microbes

Persister cells are a small subpopulation that can survive antimicrobial exposure without acquiring classic genetic resistance. They are often associated with slow growth, low metabolic activity, or temporary dormancy, which helps them tolerate drugs that work best against actively growing cells.^{[1] [2] [3]}

• The resting state: Under stress, some cells enter a low-activity state in which antimicrobial killing becomes much less effective.
• The relapse problem: After treatment pressure is removed and conditions improve, surviving persister cells can resume growth and help re-establish the infection.^{[1] [2]}

The Paradox of Traditional Treatments

Standard antimicrobials remain essential tools, but laboratory research has shown that some conditions can increase formation of persister-like cells. In one E. coli model, pretreatment with rifampicin, tetracycline, or a compound that reduced ATP production increased persistence dramatically—from a baseline around 0.01% to much higher levels, often in the 10% to 100% range depending on the model and drug challenge.^[4] A later review summarized these findings as converting an initial population of 0.01% persisters to up to approximately 80% persisters in experimental conditions.^[3]

Because of these survival mechanisms, breaking the cycle of recurrence may require more than simply repeating the same antimicrobial. Researchers are increasingly interested in strategies that disrupt biofilm structure, improve drug penetration, or target dormant cells so conventional antimicrobials can work more effectively.^{[2] [3]}

Scientific References

1. Lewis K. Persister cells and the riddle of biofilm survival. Biochemistry (Moscow). 2005;70(2):267-274. doi:10.1007/s10541-005-0111-6. PubMed.
2. Fauvart M, De Groote VN, Michiels J. Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. Journal of Medical Microbiology. 2011;60(Pt 6):699-709. doi:10.1099/jmm.0.030932-0. PubMed.
3. Wood TK. Strategies for combating persister cell and biofilm infections. Microbial Biotechnology. 2017;10(5):1054-1056. doi:10.1111/1751-7915.12774. PubMed.
4. Kwan BW, Valenta JA, Benedik MJ, Wood TK. Arrested protein synthesis increases persister-like cell formation. Antimicrobial Agents and Chemotherapy. 2013;57(3):1468-1473. doi:10.1128/AAC.02135-12. PubMed.